There is no cure for BPD, but Dr. Bernard Thbaud and his team are hoping to change that. The team previously found that cells from the umbilical cord, called mesenchymal stromal cells or MSCs, could prevent BPD in newborn rats.
Known as MSC-EVs or nanotherapies, these nano-sized particles have similar effects to MSCs but are easier to manufacture, store, and dose. Unlike MSCs, they can cross the blood-brain barrier, meaning they can travel into the brain after being injected into the blood stream. The researchers saw evidence that some MSC-EVs did reach the brain in this study, though most travelled to the lungs.
Not only did MSC-EVs prevent lung injury in this study, they also prevented brain injury. This was the first study to show that BPD impairs some of the key functions of brain stem cells. Brain stem cells can become all the different cells in the brain, and play an important role in brain development.
This study comes as Dr. Thbaud and his research team prepare to launch a phase I clinical trial to test the feasibility and safety of using MSCs to treat premature babies with BPD. They hope to evaluate MSC-EVs in future clinical trials.
“A therapy that improves lung and brain health would immensely benefit preterm babies with this chronic lung disease.” -Dr. Bernard Thbaud, neonatologist and senior scientist at The Ottawa Hospital and CHEO and professor at the University of Ottawa.
Source: Eurekalert
